Mood alterations in patients treated with chlorambucil.
The alkylating agent chlorambucil produces dose-limiting myelosuppression but can also cause rare central nervous system toxicities, including seizures, when given in high doses. Patients with lymphoma who were receiving intermittent pulsed oral doses of 10-12 mg/m2 chlorambucil per day for 5 days experienced marked mood alterations during therapy. These effects, which have not been reported previously, involved sleep alterations, anxiety and restlessness, irritability, and depression. All effects remitted immediately after the final day of the dosing regimen. Mood alterations should be added to the known list of chlorambucil-related toxicities and can occur with commonly used oral dosing schedules.
Hehn
Sean T
ST
Arizona Cancer Center, The University of Arizona, Tucson, USA.
Dorr
Robert T
RT
Miller
Thomas P
TP
D000328:Adult; D000339:Affect / Q000187:drug effects*; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use*; D002490:Central Nervous System / Q000187:drug effects; D002699:Chlorambucil / Q000009:adverse effects* / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D018906:Antineoplastic Agents, Alkylating; D002699:Chlorambucil